Reducing cardiovascular risk in patients with type 2 diabetes: Management of dyslipidemia

Research output: Contribution to journalReview article

Abstract

Patients with diabetes are at extremely high risk for cardiovascular disease. Because glucose control is associated with the only modest reduction in macrovascular complications, efforts must be made to specifically target other cardiovascular risk factors. Diabetes is associated with a characteristic lipid profile: low high-density protein cholesterol (HDL-C) and high triglyceride levels with or without high low-density lipoprotein cholesterol (LDL-C) levels. This profile is also found in patients with early onset coronary heart disease and correlates with increased atherogenesis. Multiple clinical trials have demonstrated that lipid-modifying therapy in patients with diabetes decreases cardiovascular risk. Management targeting all lipid abnormalities may represent the best treatment strategy since many patients with diabetes do not have elevated LDL-C levels. Combining lipid-modifying agents is also an attractive option for normalizing multiple lipid abnormalities.

Original languageEnglish
Pages (from-to)478-497
Number of pages20
JournalFormulary
Volume38
Issue number8
StatePublished - Aug 1 2003

Fingerprint

Dyslipidemias
Type 2 Diabetes Mellitus
Lipids
LDL Cholesterol
HDL Cholesterol
Multiple Abnormalities
Coronary Disease
Atherosclerosis
Triglycerides
Cardiovascular Diseases
Clinical Trials
Glucose
Therapeutics
Proteins

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Reducing cardiovascular risk in patients with type 2 diabetes : Management of dyslipidemia. / Hilleman, Daniel E.

In: Formulary, Vol. 38, No. 8, 01.08.2003, p. 478-497.

Research output: Contribution to journalReview article

@article{350918ad86354d1b9502310cea13cf79,
title = "Reducing cardiovascular risk in patients with type 2 diabetes: Management of dyslipidemia",
abstract = "Patients with diabetes are at extremely high risk for cardiovascular disease. Because glucose control is associated with the only modest reduction in macrovascular complications, efforts must be made to specifically target other cardiovascular risk factors. Diabetes is associated with a characteristic lipid profile: low high-density protein cholesterol (HDL-C) and high triglyceride levels with or without high low-density lipoprotein cholesterol (LDL-C) levels. This profile is also found in patients with early onset coronary heart disease and correlates with increased atherogenesis. Multiple clinical trials have demonstrated that lipid-modifying therapy in patients with diabetes decreases cardiovascular risk. Management targeting all lipid abnormalities may represent the best treatment strategy since many patients with diabetes do not have elevated LDL-C levels. Combining lipid-modifying agents is also an attractive option for normalizing multiple lipid abnormalities.",
author = "Hilleman, {Daniel E.}",
year = "2003",
month = "8",
day = "1",
language = "English",
volume = "38",
pages = "478--497",
journal = "Formulary",
issn = "1082-801X",
publisher = "Advanstar Communications",
number = "8",

}

TY - JOUR

T1 - Reducing cardiovascular risk in patients with type 2 diabetes

T2 - Management of dyslipidemia

AU - Hilleman, Daniel E.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Patients with diabetes are at extremely high risk for cardiovascular disease. Because glucose control is associated with the only modest reduction in macrovascular complications, efforts must be made to specifically target other cardiovascular risk factors. Diabetes is associated with a characteristic lipid profile: low high-density protein cholesterol (HDL-C) and high triglyceride levels with or without high low-density lipoprotein cholesterol (LDL-C) levels. This profile is also found in patients with early onset coronary heart disease and correlates with increased atherogenesis. Multiple clinical trials have demonstrated that lipid-modifying therapy in patients with diabetes decreases cardiovascular risk. Management targeting all lipid abnormalities may represent the best treatment strategy since many patients with diabetes do not have elevated LDL-C levels. Combining lipid-modifying agents is also an attractive option for normalizing multiple lipid abnormalities.

AB - Patients with diabetes are at extremely high risk for cardiovascular disease. Because glucose control is associated with the only modest reduction in macrovascular complications, efforts must be made to specifically target other cardiovascular risk factors. Diabetes is associated with a characteristic lipid profile: low high-density protein cholesterol (HDL-C) and high triglyceride levels with or without high low-density lipoprotein cholesterol (LDL-C) levels. This profile is also found in patients with early onset coronary heart disease and correlates with increased atherogenesis. Multiple clinical trials have demonstrated that lipid-modifying therapy in patients with diabetes decreases cardiovascular risk. Management targeting all lipid abnormalities may represent the best treatment strategy since many patients with diabetes do not have elevated LDL-C levels. Combining lipid-modifying agents is also an attractive option for normalizing multiple lipid abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=0042237929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042237929&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0042237929

VL - 38

SP - 478

EP - 497

JO - Formulary

JF - Formulary

SN - 1082-801X

IS - 8

ER -